Publications

Media, scientific publications and conference abstracts

Read about NEO and the science behind our technology

Liquid biopsies transform lung cancer therapy. 2016. MedNous. April, page 13.
pdf-Datei

Neue Technologie zur Tumordiagnostik. 2016. ÄrzteZeitung. No. 37-65D.
pdf-Datei

Neue Technologie für die molekulare Tumordiagnostik: Nachweis aller relevanten Genveränderungen an einer Tumorprobe. 2015. Der Onkologe. Volume 21, issue 10.
pdf file

Molekulare Diagnostik beim nicht-kleinzelligen Bronchialkarzinom: Neue Technologie zum raschen Nachweis aller therapierelevanten Genanomalien. 2015. Der Pneumologe. Volume 12, issue 6.
pdf file

Gautschi O, Menon R, Bertrand M, Murer C, Diebold J. Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. 2020. J Thorac Oncol. Jan;15(1):e13-e15. doi: 10.1016/j.jtho.2019.07.027. PubMed PMID: 31864554.
https://www.jto.org/article/S1556-0864(19)30657-4/abstract

Michels S et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. 2019. J Thorac Oncol. 14(7):1266-1276.
https://www.ncbi.nlm.nih.gov/pubmed/30978502

Ackermann S et al. A mechanistic classification of clinical phenotypes in neuroblastoma. 2018. Science. 362(6419):1165-1170.
http://science.sciencemag.org/content/362/6419/1165

Plenker D et al. Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients. 2017. Clin Cancer Res. Accepted manuscript available online.
http://clincancerres.aacrjournals.org/content/early/2017/12/28/1078-0432.CCR-17-3001

Müller JN et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. 2017. J Thorac Oncol. 15(10):1503-1511.
https://doi.org/10.1016/j.jtho.2017.07.014

Michels SYF et al. ALK^G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. 2017. npj Precision Oncology. 1:4.
https://www.nature.com/articles/s41698-017-0004-3

Heuckmann JM et al. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. 2017. J Thorac Oncol 12(3):e22-e24.
https://www.ncbi.nlm.nih.gov/pubmed/28215724

Menon R et al. A novel EGFR^C797 variant detected in a pleural biopsy from an Osimertinib-treated patient using a comprehensive hybrid-capture based next-generation sequencing assay. 2016. J Thorac Oncol. 11(9):e105-7.
http://www.jto.org/article/S1556-0864(16)30090-9/abstract

Rooney C et al. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. 2016. PLoS One. 11:e0149628.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764357/

Gautschi O et al. Successful AZD9291 Therapy Based on Circulating T790M. 2015. J Thorac Oncol. 10:e122-3.
http://www.jto.org/article/S1556-0864(15)35115-7/abstract

Gautschi O et al. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. 2015. Once Res Treat. 38:560-9.
http://www.karger.com/Article/FullText/441367

Peifer M et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. 2015. Nature. 526:700-4.
http://www.ncbi.nlm.nih.gov/pubmed

Heuckmann JM and Thomas RK. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. 2015. Ann Oncol. 26:1830-7.
http://annonc.oxfordjournals.org/content/26/9/1830.long

George J et al. Comprehensive genomic profiles of small cell lung cancer. 2015. Nature. 524:47-53.
http://www.ncbi.nlm.nih.gov/pubmed

Schramm A et al. Mutual dynamics between primary and relapse neuroblastomas. 2015. Nat Genet. 47:872-7.
http://www.ncbi.nlm.nih.gov/pubmed

Dietlein F et al. Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. 2015. Cell. 162:146-59.
http://www.ncbi.nlm.nih.gov/pubmed

Scheffler M et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. 2015. J Thorac Oncol. 10:e40-3.
http://www.ncbi.nlm.nih.gov/pubmed

Kloth M et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2015. Gut.
http://www.ncbi.nlm.nih.gov/pubmed

Mazières J et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015. J Clin Oncol. 33:992-9.
http://www.ncbi.nlm.nih.gov/pubmed

Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. 2014. Nature. 511:543-50.
http://www.nature.com/nature/journal/v511/n7511/full/nature13385.html

Fernandez-Cuesta L et al. CD74-NRG1 fusion in lung adenocarcinoma. 2014. Cancer Discov. 4:415-22.
http://cancerdiscovery.aacrjournals.org/content/4/4/415.long

Thomas RK. Overcoming drug resistance in ALK-rearranged lung cancer. 2014. N Engl J. 370:1250-1.
http://www.ncbi.nlm.nih.gov/pubmed

Fernandez-Cuesta L et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. 2014. Nat Commun. 5:3518.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132974/

Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. 2013. Sci Transl Med. 5:209ra153.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006630/

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. 2012. Nature. 489:519-25.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466113/

Heuckmann JM et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibitor in lung cancer. 2012. J Clin Oncol. 30:3417-20.
http://www.ncbi.nlm.nih.gov/pubmed

Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012. Nat Genet. 44:1104-10.
http://www.ncbi.nlm.nih.gov/pubmed

Chmielecki J et al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012. Genes Chromosomes Cancer. 51:54-65.
http://onlinelibrary.wiley.com/doi/10.1002/gcc.20930/epdf

Heuckmann JM et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011. Clin Cancer Res. 17:7394-401.
http://clincancerres.aacrjournals.org/content/17/23/7394.long

Weiss J et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010. Sci Transl Med. 2:62-93.
http://www.ncbi.nlm.nih.gov/pubmed

Chmielecki J et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010. Nucleic Acids Res. 38:6958-96.
http://nar.oxfordjournals.org/content/38/20/6985.long

Thomas RK et al. High-throughput oncogene mutation profiling in human cancer. 2007. Nat Genet. 39:347-51.
http://www.ncbi.nlm.nih.gov/pubmed

Thomas RK et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006. Nat Med. 12:852-5.
http://www.ncbi.nlm.nih.gov/pubmed

Mueller J et al. Comparison of genomic alterations derived from matched tumor tissue and liquid biopsy. WCLC 2016. Abstract P2.03b-081.
Abstract. Poster.

Wiest G et al. Detection of an EGFR Kinase Domain Duplication in a Lung Adenocarcinoma Patient by Liquid Biopsy using Hybrid Capture-based Next Generation Sequencing. DGHO 2016. Abstract 291.
Abstract. Poster.

Mueller J et al. Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies. ESMO 2016. Abstract 2761.
Abstract. Poster.

Heukamp L et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology- NEOplus and NEOliquid. ASCO 2016. Abstract e23181.
Abstract.

Menon R et al. Identification of Therapeutically Targetable Genomic Alterations in a cohort of patients with CUP using a Hybrid-Capture based Next Generation Sequencing Assay. AACR 2016. Abstract 152.
Abstract. Poster.

Menon R et al. NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples. ELCC 2016. Abstract 431.
Abstract. Poster.

Menon R et al. Discovery of a Novel EGFR Resistance Mutation by Capture Based NGS Following AZD9291 Treatment. Oncol Res Treat 2016;39(suppl 1):120.
Abstract. Poster.

Dziadziuszko R et al. Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics. WCLC 2015. Abstract 2748.
Abstract. Poster.

Menon R et al. Successful AZD9291 Therapy Based on NEOliquid Detection of Circulating T790M in a Liquid Biopsy Sample. 2015. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract B135.
Abstract. Poster.